Ascendiant Capital maintains Buy on Outlook Therapeutics, lowers PT to $8.

lunes, 22 de septiembre de 2025, 6:01 am ET1 min de lectura
OTLK--

Ascendiant Capital maintains Buy on Outlook Therapeutics, lowers PT to $8.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios